VRTX

Vertex Pharmaceuticals
D

VRTX

Arincen81/100B

Vertex Pharmaceuticals operating income 1990–2026

Vertex Pharmaceuticals's operating income in Q3 FY2026, the three months to 30 September 2026, was 712.90M USD, down 39.9% on the same quarter a year before. Vertex Pharmaceuticals's operating income over the last twelve months was 4.40B USD, up 10.1% on the twelve months before. In fiscal year 2025 it was 4.76B USD, against a loss of 232.90M USD on the year before.

Last updated 9 Nov 2026 · Next report 11 Feb 2027

Operating income

Operating income Operating margin

Growth

Fiscal yearPeriod endingOperating incomeGrowthOperating marginGross profitGross marginEBITDA
TTM30 Sept 20264.40B+10.15%33.87%11.11B85.57%4.97B
FY202531 Dec 20254.76B—39.43%10.27B85.03%4.87B
FY202431 Dec 2024-232.90M-106.08%-2.11%9.49B86.11%486.30M
FY202331 Dec 20233.83B-11.04%38.83%8.61B87.21%4.61B
FY202231 Dec 20224.31B+54.83%48.23%7.85B87.90%4.44B
FY202131 Dec 20212.78B-2.60%36.73%6.67B88.06%2.92B
FY202031 Dec 20202.86B+138.51%46.03%5.47B88.14%3.28B
FY201931 Dec 20191.20B+88.55%28.77%3.62B86.84%1.56B
FY201831 Dec 2018635.15M+415.36%20.84%2.64B86.56%706.78M
FY201731 Dec 2017123.24M+1,140.37%4.95%2.21B88.95%103.26M
FY201631 Dec 20169.94M—0.58%1.49B87.64%75.46M
FY201531 Dec 2015-468.66M—-45.40%906.79M87.84%-411.25M
FY201431 Dec 2014-692.41M—-119.30%519.43M89.49%-598.76M
FY201331 Dec 2013-903.45M-38,841.34%-74.54%1.08B89.25%-554.75M
FY201231 Dec 20122.33M-97.95%0.15%1.25B81.67%42.46M
FY201131 Dec 2011113.82M—8.07%1.33B94.29%133.94M
FY201031 Dec 2010-696.08M—-485.51%130.64M91.12%-704.89M
FY200931 Dec 2009-613.41M—-601.10%87.85M86.08%-598.88M
FY200831 Dec 2008-462.71M—-263.65%159.82M91.06%-426.19M
FY200731 Dec 2007-419.79M—-210.94%185.11M93.01%-385.21M
FY200631 Dec 2006-229.04M—-105.86%204.19M94.38%-199.52M
FY200531 Dec 2005-149.87M—-93.15%150.79M93.72%-114.45M
FY200431 Dec 2004-154.81M—-150.71%97.07M94.50%-107.59M
FY200331 Dec 2003-264.53M—-382.59%66.02M95.48%-264.53M
FY200231 Dec 2002-119.60M—-74.25%132.80M82.44%-123.05M
FY200131 Dec 2001-91.80M—-54.81%127.86M76.34%-97.14M
FY200031 Dec 2000-38.68M—-49.51%74.05M94.78%-24.65M
FY199931 Dec 1999-39.60M—-64.29%65.00M105.52%-44.30M
FY199831 Dec 1998-32.40M—-72.97%48.90M110.14%-43.20M
FY199731 Dec 1997-19.20M—-43.84%47.40M108.22%-15.60M
FY199631 Dec 1996-29.80M—-224.06%16.50M124.06%-36.30M
FY199531 Dec 1995-26.50M—-119.91%25.80M116.74%-22.80M
FY199431 Dec 1994-20.70M-1,825.00%-105.61%23.10M117.86%-17.20M
FY199331 Dec 19931.20M—4.30%31.80M113.98%5.10M
FY199231 Dec 1992-10.00M—-263.16%6.60M173.68%-7.20M
FY199131 Dec 1991-5.60M—-175.00%5.00M156.25%-3.80M
FY199031 Dec 1990-4.10M—-178.26%2.30M100.00%-4.10M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Vertex Pharmaceuticals's operating income

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.